Durand-Réville, Thomas F.
Guler, Satenig
Comita-Prevoir, Janelle
Chen, Brendan
Bifulco, Neil
Huynh, Hoan
Lahiri, Sushmita
Shapiro, Adam B.
McLeod, Sarah M.
Carter, Nicole M.
Moussa, Samir H. http://orcid.org/0000-0001-5348-596X
Velez-Vega, Camilo
Olivier, Nelson B.
McLaughlin, Robert
Gao, Ning
Thresher, Jason
Palmer, Tiffany
Andrews, Beth
Giacobbe, Robert A.
Newman, Joseph V.
Ehmann, David E.
de Jonge, Boudewijn
O'Donnell, John
Mueller, John P.
Tommasi, Rubén A.
Miller, Alita A.
Article History
Received: 9 November 2016
Accepted: 25 May 2017
First Online: 30 June 2017
Competing interests
: All authors are current or past employees of AstraZeneca or Entasis Therapeutics and may own stock from one or both companies. Entasis Therapeutics owns a granted patent on the new diazabicyclooctenone BLI series (US patent 9,309,245 B2, granted 12 April 2016).